Precision Science, Compassionate Care

OmniGenix stands at the intersection of cutting-edge cell biology and human-centered care, transforming the body’s own language of healing into precision therapeutics. Our core focus—mesenchymal stem cell–derived exosomes—delivers nano-sized signals that calm inflammation, spark tissue repair, and re-awaken dormant pathways of regeneration. Every OmniGenix vial embodies uncompromising science, stringent safety, and a promise of vitality for patients who have exhausted conventional options.

Yet technology is only part of our story. We are clinicians, researchers, and advocates united by a conviction that true progress is measured in lives restored. Through transparent data sharing, practitioner mentorship, and equitable access programs, we ensure breakthroughs travel swiftly from bench to bedside—reaching communities as diverse as the people we serve. At OmniGenix, compassion powers discovery, and discovery powers hope. Together, we are redefining what it means to heal.

Hello and welcome. I’m Cliff Layton, and I have the privilege of guiding a group of extraordinary leaders who live the quote above every single day. We wake up obsessed with one question: How can today’s data become tomorrow’s relief for patients who’ve run out of options?

Each leader you’ll meet on this page was hand-picked not merely for credentials, but for a relentless passion to translate mesenchymal stem-cell exosome science into outcomes you can feel—less pain, faster recovery, renewed possibility. They bring decades of expertise in their respective fields, yet they share one common mission: transforming breakthrough findings into safe, accessible therapies that change lives.

John Altshuler, COO | President of OmniGenix, brings three decades of trail‑blazing success in health innovation, nutraceutical manufacturing, and financial services. Renowned for spotting emerging trends and building high‑performing teams, he has launched wellness products that reached millions and powered record‑breaking growth. At OmniGenix, John couples operational rigor with a passion for equitable care, spearheading the nationwide rollout of MSC‑derived exosome therapies that promise safer, more accessible regeneration. His hallmark—combining ethical business modeling with strategic partnerships—continues to empower clinicians, patients, and entrepreneurs alike, proving that disciplined strategy can accelerate lifesaving innovation without compromising integrity.

Kendall Wood, Chief Growth & Technology Officer at OmniGenix, fuses 20 years of enterprise-scale software engineering with growth-hacker marketing to push regenerative medicine into mainstream care. He previously launched the ringless-voicemail pioneer DropVM, built compliance-ready LinkedIn and data-scraping automations, and created simulation software adopted by small businesses, universities, and large corporations like GEICO and Washington Dental Health. At OmniGenix he architects HIPAA-secure analytics, customer portals, and a Partner Accelerator that arms physicians with turnkey assets and precision geotargeting—ensuring every line of code advances equitable, responsible access to cellular regeneration nationwide.

Dr. McClane Duncan, ND, Chief Medical Officer and Clinical Educator at OmniGenix, blends two decades of naturopathic vitalism with leading‑edge regenerative science. A Bastyr‑trained, board‑certified naturopath, he has mastered prolotherapy, PRP, ozone, ultrasound‑guided injections, and integrative oncology techniques, teaching physicians worldwide to shift from symptom relief to true tissue renewal. At OmniGenix he designs MSC‑exosome protocols, oversees GMP analytics, and builds practitioner curricula that translate nanovesicle pharmacology into bedside results. Passionate about demystifying complex biology, Dr. Duncan empowers patients and clinicians alike to reactivate the body’s innate repair blueprint—one precise cellular signal at a time.

Greg McKettrick, RPh, is a nationally recognized compounding pharmacist and clinical educator with 35+ years of experience in men’s health, hormone optimization, sexual wellness, and advanced therapeutic protocols. As Chief Medical Advisor to OmniGenix, he provides clinical oversight, practitioner education, and strategic guidance across regenerative medicine, peptides, and biologic therapies. He specializes in sexual dysfunction and post-prostatectomy recovery, and developed the Post-Prostatectomy Penile Rehabilitation Protocol used by urology clinics nationwide and supported by published articles and PenileRehabProtocol.com. Greg also leads roles at Revelation Pharma, co-founded Live Harder Health, serves multiple advisory/academic posts, speaks for ZERO, and hosts the Hard Facts podcast.

Dr. Doug Yoch is a nationally respected pharmacy executive and formulation strategist with 30+ years of experience in clinical pharmacy, sterile and non-sterile compounding, regulatory compliance, and pharmaceutical leadership. He serves as Chief Medical Advisor for Pharmacy & Formulation Strategy at OmniGenix, guiding product evaluation, formulation integrity, regulatory considerations, and practitioner education across regenerative and peptide platforms. His focus is ensuring OmniGenix products and protocols meet top standards for safety, consistency, and scientific validity. He is also Director of Formulation Strategy and a shareholder at Revelation Pharma, supporting formulation development and compliance at scale, and advises Prollenium US and Ananda Professional. Formerly, he owned Stanley Specialty Pharmacy for over two decades.